§ 134.1112 The decision.

(a) Timing. The Judge shall decide a CVE Appeal, insofar as practicable, within 60 calendar days after close of the record.

(b) Contents. Following closure of the record, the Judge will issue a decision containing findings of fact and conclusions of law, reasons for such findings and conclusions, and any relief ordered.

(c) Basis for decision. Decisions under this subpart will be based primarily on the evidence in the CVE case file, arguments made on appeal, and any response(s) thereto. However, the Judge, in his/her sole discretion, may consider issues beyond those raised in the pleadings and the denial or cancellation letter.

(d) Finality. The decision is the final agency decision and becomes effective upon issuance. Where OHA dismisses an appeal of a D/CVE denial or cancellation, the D/CVE determination remains in effect.

(e) Service. OHA will serve a copy of all written decisions on each party, or, if represented by counsel, on its counsel.

(f) Effect. If the Judge grants the appeal and finds the appellant eligible for inclusion in the CVE database, the D/CVE must immediately reinstate or include the appellant, as the case may be, in the CVE database.

(g) Reconsideration. A decision of the Judge may be reconsidered. Any party that has appeared in the proceeding, or the Secretary of VA or his or her designee, may request reconsideration by filing with OHA and serving a petition for reconsideration on all parties to the CVE Appeal within twenty (20) calendar days after service of the written decision, upon a clear showing of an error of fact or law material to the decision. The Judge also may reconsider a decision on his or her own initiative.

Dated: March 14, 2018.

Linda E. McMahon, Administrator.

[FR Doc. 2018–06034 Filed 3–29–18; 8:45 am]

BILLING CODE 8025–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, 524, 556, and 558

[Docket No. FDA–2017–N–0002]

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor’s Name and Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during July, August, and September 2017. FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/ CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA’s publication, Approved Animal Drug Products Online (Green Book) at: https://www.fda.gov/AnimalVetinary/Products/ApprovedAnimalDrugProducts/default.htm.

DATES: This rule is effective March 30, 2018, except for amendatory instructions 3 to 21 CFR 510.600, 9 to 21 CFR 522.300, 10 to 21 CFR 522.540, and 11 to 21 CFR 522.1081, which are effective April 9, 2018.

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–402–5689, george.haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Approval Actions

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during July, August, and September 2017, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/ CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA’s publication, Approved Animal Drug Products Online (Green Book) at: https://www.fda.gov/AnimalVetinary/Products/ApprovedAnimalDrugProducts/default.htm.

<table>
<thead>
<tr>
<th>Approval date</th>
<th>File No.</th>
<th>Sponsor</th>
<th>Product name</th>
<th>Species</th>
<th>Effect of the action</th>
<th>Public documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 21, 2017</td>
<td>141–450</td>
<td>Intervet, Inc., 2</td>
<td>BANAMINE</td>
<td>Cattle</td>
<td>Original approval for the control of pyrexia associated with bovine respiratory disease and the control of pain associated with foot rot in steers, beef heifers, beef cows, beef bulls intended for slaughter, and replacement dairy heifers under 20 months of age.</td>
<td>FOI Summary; EA/FONSI; 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Giralda Farms,</td>
<td>Transdermal (flunixin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Madison, NJ 07940.</td>
<td>transdermal solution) Solution</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE 1—Original and Supplemental NADAs and ANADAs Approved During July, August, and September 2017—Continued

<table>
<thead>
<tr>
<th>Approval date</th>
<th>File No.</th>
<th>Sponsor</th>
<th>Product name</th>
<th>Species</th>
<th>Effect of the action</th>
<th>Public documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 15, 2017</td>
<td>141–250</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007</td>
<td>Chlortetracycline and lasalocid Type B and Type C medicated feeds. SENTINEL SPECTRUM (milbemycin oxime/lufenuron/praziquantel).</td>
<td>Cattle</td>
<td>Supplemental approval of revised representative labeling making technical amendments.</td>
<td>FOI Summary.</td>
</tr>
</tbody>
</table>

The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI).

II. Change of Sponsorship

SmartVet USA, Inc., 22201 West Innovation Dr., suite 170A, Olathe, KS 66061–1304 has informed FDA that it has transferred ownership of, and all rights and interest in, the following application to Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215:

| File No. 200–348 | Product name ECOMECTIN (ivermectin) Topical Solution | 21 CFR Section 524.1193 |

Following this withdrawal of approval, SmartVet USA, Inc. is no longer the sponsor of an approved application. Accordingly, it will be removed from the list of sponsors of approved applications in §510.600(c) (21 CFR 510.600(c)).

Strategic Veterinary Pharmaceuticals, Inc., 100 NW. Airport Rd., St. Joseph, MO 64503 has informed FDA that it has transferred ownership of, and all rights and interest in, the following application to Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland:

| File No. 109–305 | Product name Oxytocin Injection | 21 CFR Section 522.1680 |

The animal drug regulations are being amended to reflect these changes of sponsorship.

III. Withdrawals of Approval

The following sponsors requested that FDA withdraw approval of the NADAs listed in the following table because the products are no longer manufactured or marketed:

| File No. 104–606 | Sponsor Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA 92880 | Product name Dexamethasone Sodium Phosphate Injection | 21 CFR Section 522.540 |
Following this withdrawal of approval, Watson Laboratories, Inc. is no longer the sponsor of an approved application. Accordingly, it will be removed from the list of sponsors of approved applications in §510.600(c).

Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADAs 047–055, 104–606, and 139–633, and all supplements and amendments thereto, is withdrawn, effective April 9, 2018. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these actions.

IV. Technical Amendments

Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA 98248 has informed FDA that it has changed its name and address to Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248.

ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115 has informed FDA that it has changed its name to ADM Animal Nutrition, Inc. Accordingly, we are amending §510.600(c) to reflect these changes.

We are also making technical amendments to update the scientific name of a pathogenic bacterium, to accurately list the concentrations of ingredients in a combination new animal drug, and to correctly list the assay limits and maximum drug concentration in Type B medicated feeds for a combination new animal drug used in feed. These actions are being taken to improve the accuracy of the regulations.

V. Legal Authority

This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)), which requires Federal Register publication of “notice[s] . . . effective as a regulation,” of the conditions of use of approved new animal drugs. This rule sets forth technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities.

Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as “an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.”

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, and 524
Animal drugs.

21 CFR Part 556
Animal drugs, Food.

21 CFR Part 558
Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 520, 522, 524, 556, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for part 510 continues to read as follows:


2. In §510.600, in the table in paragraph (c)(1), remove the entries for "ADM Alliance Nutrition, Inc.", "SmartVet USA, Inc." and "Western Chemical, Inc.", and add entries for "ADM Animal Nutrition, Inc." and "Syndel USA" in alphabetical order; and in the table in paragraph (c)(2), remove the entry for "086001" and revise the entries for "012286" and "050378" to read as follows:

§510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>* * * * * * * * *</td>
<td>ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115</td>
</tr>
<tr>
<td>* * * * * * * * *</td>
<td>Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248</td>
</tr>
</tbody>
</table>

2. In §510.600, in the table in paragraph (c)(1), remove the entries for "ADM Alliance Nutrition, Inc.", "SmartVet USA, Inc." and "Western Chemical, Inc.", and add entries for "ADM Animal Nutrition, Inc." and "Syndel USA" in alphabetical order; and in the table in paragraph (c)(2), remove the entry for "086001" and revise the entries for "012286" and "050378" to read as follows:
3. Effective April 9, 2018, in § 510.600, in the table in paragraph (c)(1), remove the entry for “Watson Laboratories, Inc.”; and in the table in paragraph (c)(2), remove the entry for “000402”.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

4. The authority citation for part 520 continues to read as follows: Authority: 21 U.S.C. 360b.

§ 520.48 [Amended]
5. In § 520.48, in paragraph (b), remove “000061 and 061623” and in its place add “000061, 051072, and 061623”.

§ 520.1447 [Amended]
6. In § 520.1447, in paragraph (d)(1)(ii), remove “(Taenia pisiformis, Echinococcus multilocularis, and E. granulosus)” and in its place add “(Dipylidium caninum, Taenia pisiformis, Echinococcus multilocularis, and E. granulosus)”.

7. In § 520.2645, revise paragraphs (d)(1) and (2) to read as follows:

§ 520.2645 Tylvalosin.

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>050378</td>
<td>Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248.</td>
</tr>
</tbody>
</table>

§ 522.300 [Removed]
9. Effective April 9, 2018, remove § 522.300.

10. Effective April 9, 2018, in § 522.540, revise paragraphs (b)(2) and (c)(2) to read as follows:

§ 522.540 Dexamethasone solution.

(b) * * * (2) Sponsor. See No. 061623 in § 510.600(c) of this chapter.

(c) * * * (2) Sponsor. See No. 061623 in § 510.600(c) of this chapter.

§ 522.1081 [Amended]
11. Effective April 9, 2018, in § 522.1081, in paragraph (b)(1), remove “Nos. 000402 and 054771” and in its place add “No. 054771”.

§ 522.1662a [Amended]
12. In § 522.1662a, in paragraph (b)(3)(ii), remove “Spherophorus necrophorum” and in its place add “Fusobacterium necrophorum”.

§ 522.1680 [Amended]
13. In § 522.1680, in paragraph (b), remove “054628,”.

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

14. The authority citation for part 524 continues to read as follows: Authority: 21 U.S.C. 360b.

15. Add § 524.970 to read as follows:

§ 524.970 Flunixin.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) flunixin (equivalent to 83 mg flunixin meglumine).

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.286 of this chapter.

(d) Conditions of use—(1) Amount. Apply only once at a dose of 3.3 mg flunixin per kg body weight (1.5 mg/lb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the withers to the tailhead.

(2) Indications for use. For the control of pyrexia associated with bovine respiratory disease and the control of pain associated with foot rot in steers, beef heifers, beef cows, beef bulls intended for slaughter, and replacement dairy heifers under 20 months of age.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Cattle must not be slaughtered for human consumption within 8 days of the last treatment. Not for use in female dairy cattle 20 months of age or older, including dry dairy cows; use in these cattle may cause drug residues in milk and/or in calves born to these cows or heifers. Not for use in suckling beef calves, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.

16. In § 524.1132, revise paragraph (a) to read as follows:

§ 524.1132 Hydrocortisone, miconazole, and gentamicin otic suspension.

(a) Specifications. Each milliliter (mL) of suspension contains 1.11 milligrams (mg) hydrocortisone aceponate, 17.4 mg miconazole nitrate, and 1.5 mg gentamicin (as gentamicin sulfate).

PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

18. The authority citation for part 556 continues to read as follows:


§ 556.286 [Amended]
19. In § 556.286, in paragraph (c), remove §§ 522.956 and 522.970” and in its place add “§§ 522.956, 522.970, and 524.970”.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

20. The authority citation for part 558 continues to read as follows:

§ 558.4 Requirement of a medicated feed mill license.

* * * * *

**CATEGORY II**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Assay limits percent (^1) Type A (^1)</th>
<th>Type B maximum ((100\times))</th>
<th>Assay limits percent (^1) Type B/C (^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neomycin</td>
<td>80–120 20 g/lb (4.4%)</td>
<td></td>
<td>70–125</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>80–120 20 g/lb (4.4%)</td>
<td></td>
<td>65–135</td>
</tr>
<tr>
<td>Neomycin sulfate</td>
<td>80–120 100 g/lb (22.0%)</td>
<td></td>
<td>70–125</td>
</tr>
<tr>
<td>Narasin</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td></td>
<td>85–115/75–125</td>
</tr>
<tr>
<td>Nicarbazin (granular)</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td></td>
<td>85–115/75–125</td>
</tr>
<tr>
<td>Nicarbazin (powder)</td>
<td>98–106 5.675 g/lb (1.25%)</td>
<td></td>
<td>85–115/80–120</td>
</tr>
<tr>
<td>Novobiocin</td>
<td>85–115 17.5 g/lb (3.85%)</td>
<td></td>
<td>80–120</td>
</tr>
<tr>
<td>Pyrantel tartrate</td>
<td>90–110 36 g/lb (7.9%)</td>
<td></td>
<td>75–125</td>
</tr>
</tbody>
</table>

\(^1\) Percent of labeled amount.

\(^2\) Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed.

22. In § 558.128, revise paragraphs (e)(3)(vi), (e)(4)(ix), and (e)(4)(xxvi) to read as follows:

**§ 558.128 Chlortetracycline.**

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(vi) 10 mg/lb of body weight.</td>
<td>Tiamulin hydrogen fumarate, 35.</td>
<td>For control of swine dysentery associated with <em>Brachyspira</em> (formerly <em>Serpulina</em> or <em>Treponema</em> hyodysenteriae) susceptible to tiamulin and for treatment of swine bacterial enteritis caused by <em>E. coli</em> and <em>Salmonella choleraesuis</em> sensitive to chlortetracycline and treatment of bacterial pneumonia caused by <em>P. multocida</em> sensitive to chlortetracycline.</td>
<td>Feed chlortetracycline at approximately 400 g/ton of feed, varying with body weight and food consumption, to provide 10 mg/lb of body weight. Feed continuously as the sole ration for 14 days. Withdraw medicated feed 2 days before slaughter. Tiamulin as provided by Nos. 058198 or 069254 in § 510.600(c) of this chapter.</td>
<td>058198 069254</td>
</tr>
</tbody>
</table>

(4) * * *

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
</table>
(ix) 500 to 4,000 to provide 10 mg/lb of body weight daily.

LaSalocid, 30 to 600 grams/ton

Pasture cattle (slaughter, stocker, feeder cattle, dairy and beef replacement heifers): For treatment of bacterial enteritis caused by E. coli and bacterial pneumonia caused by P. multocida organisms susceptible to chlortetracycline; and for increased rate of weight gain.

Feed continuously on a hand-fed basis for not more than 5 days to provide 10 mg chlortetracycline per lb. body weight per day and not less than 60 mg or more than 300 mg lasalocid per head per day in at least 1 pound of feed. Daily lasalocid intakes in excess of 200 mg/head/day in pasture cattle have not been shown to be more effective than 200 mg lasalocid/head/day. Do not allow horses or other equines access to feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. See §558.311(d) of this chapter. Lasalocid as provided by No. 054771 in §510.600(c) of this chapter.

054771

(xxvi) 500 to 4,000 to provide 10 mg/head/day.

LaSalocid, 30 to 181.8

Cattle weighing up to 800 pounds: For the treatment of bacterial enteritis caused by E. coli and bacterial pneumonia caused by P. multocida susceptible to chlortetracycline; and for the control of coccidiosis caused by Eimeria bovis and E. zuernii.

Hand feed continuously for not more than 5 days at a rate of 10 mg chlortetracycline and 1 mg lasalocid per 2.2 lb. body weight daily to cattle with a maximum of 360 mg of lasalocid per head per day. Do not allow horses or other equines access to feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. See §558.311(d) of this chapter. Lasalocid as provided by No. 054771 in §510.600(c) of this chapter.

054771

23. In §558.325, revise paragraph (d)(2) to read as follows:

§558.325 Lincomycin.

(2) The expiration date of VFDs for lincomycin medicated feeds must not exceed 6 months from the date of issuance. VFDs for lincomycin shall not be refilled.

§558.575 [Amended]

24. In §558.575, in paragraph (e)(2)(ii) remove “and bacterial infections due to H. galmaxima,”.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of three new animal drug applications (NADAs). This action is being taken at the sponsors’ request because these products are no longer manufactured or marketed.

DATES: Withdrawal of approval is effective April 9, 2018.

FOR FURTHER INFORMATION CONTACT: Sujaya Dessai, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–402–5761, sujaya.dessai@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: During July and August 2017, the following sponsors requested that FDA withdraw approval of the NADAs listed in the following table because the products are no longer manufactured or marketed: